Proportion of participants achieving clear or almost clear skin (PASI 90 to 100 or PGA 0 to 1) · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Percentage of participants with adverse effects and severe adverse effects · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of relapses of guttate psoriasis or flares within a period of 6 months after the treatment has finished · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants achieving PASI 75 or PGA 1 to 2 · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in participant satisfaction measures and quality of life assessment measures Overall subjective score on 5 items (appearance of lesions, impairment of daily life, pruritus, burning, and pain) reported through figures · guttate psoriasis
1 finding from 1 review
All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).
1 finding from 1 review
28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) probably leads to lower all‐cause mortality, adults, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
5 findings from 1 review
RR 0.81 [0.7, 0.93]
10 studies · 1430 participants
Moderate
RR 0.66 [0.51, 0.85]
7 studies · 528 participants
Moderate
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High
Show 2 more findings
Risk of requiring allogeneic blood transfusion (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid may leads to lower risk of requiring allogeneic blood transfusion (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Re‐operation due to bleeding (7 days post‐surgery) ‐ not reported · people undergoing definitive fixation of hip, pelvic and long bone fractures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Myocardial infarction (0 to 30 days) · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of myocardial infarction (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Stroke · people undergoing definitive fixation of hip, pelvic and long bone fractures
Intravenous tranexamic acid showed no clear difference in risk of cerebrovascular accident/stroke (30 days post‐surgery) compared with placebo (low certainty).
1 finding from 1 review
Deep vein thrombosis · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of deep vein thrombosis (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Risk of suspected serious drug reactions (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures
It is very uncertain whether intravenous tranexamic acid changes risk of suspected serious drug reactions (30 days post‐surgery) compared with placebo (very low certainty).
1 finding from 1 review
Adverse events: thromboses · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: thromboses compared with oral steroids alone (very low certainty).
1 finding from 1 review
Gastrointestinal bleeding · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes adverse events: gastrointestinal bleeding compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete remission · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes complete remission Time frame: 2 to 28 months compared with oral steroids alone (very low certainty).
1 finding from 1 review
Complete or partial remission · minimal change disease in adults with nephrotic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · minimal change disease in adults with nephrotic syndrome
It is very uncertain whether intravenous ± oral steroids changes relapse during compared with oral steroids alone (very low certainty).
1 finding from 1 review